STK11 and cancer: Moreover, previous studies in other cancer subtypes have demonstrated that specific genomic alterations can also contribute to immune evasion and impede immunotherapy, including b2-microglobulin mutations that can cause impairment of antigen presentation by disrupting MHC class I [58,59]; JAK1/2 [59] and STK11 [60] mutations; WNT/b-catenin pathway alterations [61,62]; and PTEN loss [63].